Clinical Trials
109
41 active
Approvals
0
Total approvals
Agencies
0
Regulatory bodies
Founded
1948
Active, not recruiting
20
18.4%
Completed
43
39.5%
Not yet recruiting
21
19.3%
Recruiting
18
16.5%
Suspended
3
2.8%
Terminated
3
2.8%
Unknown
1
0.9%
No approval data available
- Takeda Biopharmaceuticals India and Dr Reddy's Laboratories have entered a distribution agreement covering QDENGA, India's first approved dengue vaccine, in the country's private market. - Dr Reddy's will exclusively promote and distribute QDENGA for paediatric and adult vaccination, with availability anticipated in the first half of 2027 pending local authority processes. - The deal follows CDSCO marketing authorisation in July 2026 for individuals aged 4 to 60 years, and Takeda retains public-market rights plus medical and brand oversight. - Dengue cases in India have risen 11-fold over two decades, and a nationwide ICMR surveillance study found all four serotypes co-circulating, with 1 in 14 patients infected with multiple serotypes.
- WHO and Global Platform partners launched a 2026-2030 market shaping strategy to fix fragile supply of essential childhood cancer medicines in low- and middle-income countries. - A baseline assessment of 51 hospitals in 12 countries found only about 45% of essential childhood cancer medicines were available. - WHO issued its first prequalification invitation covering six established medicines: pegaspargase, asparaginase, hydrocortisone, dactinomycin, vincristine and cytarabine. - The strategy sets out ten interlinked interventions including pooled procurement, volume guarantees and voluntary licensing for newer therapies.
- NanoViricides' Phase IIA/IIB trial of oral NV-387 gummies for Bundibugyo Ebolavirus is set to start next week at an Ebola treatment center in Ituri province, DRC. - The adaptive trial adds an oral option to the WHO-linked PARTNERS study, which is evaluating infused MBP134 and remdesivir in roughly 300 enrolled patients. - As of September 10, 2026, DRC has reported 7,022 confirmed cases, 3,398 confirmed deaths and 1,671 recoveries, with a crude fatality rate near 48%.
- The World Health Organization has opened a public consultation on improving the inclusion of underrepresented populations in clinical trials, running from 14 September to 29 October 2026. - The consultation seeks views on current challenges, barriers to participation, priorities for improving inclusion and actions to strengthen trial design, recruitment, reporting, accountability and community engagement. - Findings will feed into recommendations developed under a WHO-supported international project led by Cochrane Response, with consultation activities led by researchers at La Trobe University.
- Gilead Sciences and the Pan American Health Organization signed an agreement to accelerate access to twice-yearly lenacapavir for HIV pre-exposure prophylaxis across all PAHO Member States. - The deal uses PAHO's Regional Revolving Funds to create a coordinated regional procurement pathway, adding 14 countries outside Gilead's existing voluntary licensing agreements. - PAHO estimates roughly 140,000 new HIV infections occur annually in Latin America and the Caribbean, where new infections rose 13% between 2010 and 2024. - Lenacapavir is a first-in-class HIV capsid inhibitor with a multi-stage mechanism of action and no known in-vitro cross-resistance to existing antiretroviral classes.
- Bayer's Monsanto unit appeared before a Missouri state court seeking final approval of a $7.25 billion settlement covering roughly 65,000 Roundup claims alleging non-Hodgkin lymphoma. - Judge Timothy Boyer of the Missouri Circuit Court in St. Louis heard objections from plaintiffs' attorneys who argue the deal blocks claimants from taking their cases to trial. - The settlement follows a June Supreme Court ruling that FIFRA preempts state failure-to-warn claims where the EPA has confirmed product safety. - Bayer's pharmaceutical arm meanwhile secured FDA approvals for sevabertinib in lung cancer and an expanded Kerendia indication in chronic kidney disease with type 1 diabetes.
- WHO granted prequalification to a three-dose vial presentation of Pfizer's maternal RSV vaccine Abrysvo, enabling large-scale distribution in lower-income countries. - RSV is the second leading cause of infant mortality globally after malaria, with over 100,000 deaths annually in children under five and more than 97% in low- and middle-income countries. - Pivotal Phase 3 trials showed 81.8% efficacy against severe RSV-associated lower respiratory disease in infants' first 90 days, sustained at 69.4% through six months.
- Egypt's drug regulator secured WHO prequalification for its pharmaceutical quality control laboratories, the first Egyptian regulatory labs to earn the designation. - The EDA already holds WHO Maturity Level 3 for both medicines and vaccines, making Egypt the first African country to reach that milestone in both fields. - Prime Minister Mostafa Madbouly met EDA Chairman Ali El-Ghamrawy to review progress toward WHO Maturity Level 4 accreditation. - Officials say the recognition should boost confidence in Egyptian-made medicines and ease their access to global markets.
- India's Supreme Court declined to entertain a PIL challenging the national HPV vaccination programme, warning that unverified vaccine claims could derail a public health initiative. - The bench noted that WHO recommends the HPV vaccine and that ordinary compensation rules apply to any adverse events following immunisation. - Petitioner Universal Health Organisation sought suspension of school-based HPV vaccination pending a legally compliant informed consent protocol and a vaccine injury compensation scheme. - The petition was withdrawn after the Court indicated it would make harsh observations against the doctors' group behind the challenge.
- The ongoing Ebola outbreak in the Democratic Republic of Congo has killed more than 3,000 people since mid-May, with mortality exceeding 60% among children under age 5. - The EBO-PEP study of the experimental antiviral obeldesivir initially excluded children under 30 kg, though protocols may soon expand to include those over 20 kg. - Doctors Without Borders and pediatric experts argue children and pregnant women must be included in clinical trials from the outset rather than at later stages. - A Berlin case showed the experimental antibody MBP134 was well tolerated in children as young as 1 year old, offering a foundation for future pediatric studies.
